High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis

•A short-duration, pangenotypic cure for HCV infection may help treat more patients.•Glecaprevir plus pibrentasvir (G/P) therapy for 8 weeks had an overall cure rate of 98%.•The efficacy of 12-week G/P therapy (99%) was not significantly higher than that of 8-week G/P therapy (p = 0.2).•Treatment responses were high irrespective of any baseline patient or viral trait.•G/P demonstrated a favourable safety profile regardless of treatment duration....